Development of versatile bio-stable oral polymeric delivery systems for proteins

An oral proteomatrix drug delivery platform was formulated using pH responsive biostable polymers for slow release kinetics for the treatment of the neurodegenerative disease, multiple sclerosis (MS), which was the primary aim. After successful design and optimization for utilizing this system fo...

Full description

Bibliographic Details
Main Author: Kondiah, Pierre Pavan Demarco
Format: Others
Language:en
Published: 2015
Subjects:
Online Access:http://hdl.handle.net/10539/18658
id ndltd-netd.ac.za-oai-union.ndltd.org-wits-oai-wiredspace.wits.ac.za-10539-18658
record_format oai_dc
spelling ndltd-netd.ac.za-oai-union.ndltd.org-wits-oai-wiredspace.wits.ac.za-10539-186582019-05-11T03:41:19Z Development of versatile bio-stable oral polymeric delivery systems for proteins Kondiah, Pierre Pavan Demarco Drug Delivery Systems An oral proteomatrix drug delivery platform was formulated using pH responsive biostable polymers for slow release kinetics for the treatment of the neurodegenerative disease, multiple sclerosis (MS), which was the primary aim. After successful design and optimization for utilizing this system for MS, this system was further applied as a versatile platform for oral protein delivery. Interferon beta (INF- ) was selected as the oral treatment for MS. The fundamental effect of INF- in the treatment of MS is based on reducing the immune response that is directed against central nervous system myelin, i.e. the fatty sheath that surrounds and protects nerve fibers. Damage of nerve fibers, resulting in demyelination, consequently causes nerve impulses to be slowed or halted, thus producing symptoms of MS (Jongen et al., 2011). To date, INF- is effectively being used to treat MS subcutaneously or as intramuscular injections. These forms of administration have commonly been associated with multiple problems of pain, allergic reactions, poor patient compliance and chances of infection (Chiu et al., 2007). It was thus concluded to design an oral platform for the delivery of multiple protein therapeutic formulations. To prove the versatility of the proteomatrix system, two other demanding protein therapeutics for oral delivery, insulin and erythropoietin, were selected for further in vitro Box-Behnken series of formulations and in vivo analysis. By administration of these oral protein systems, a greater patient compliance can be achieved, thus enhancing the therapeutic profiles of patients with conditions of MS, diabetes and chronic renal failure resulting in chronic anemia. All studies consisted of in vitro drug release studies, characterization using specific analytical techniques for testing the mechanical properties, as well as the physicochemical characteristics of the copolymeric system. All proteins, INF- , insulin and erythropoietin, were analyzed in vivo using New Zealand White rabbits (NZW) with determination of the protein from serum obtained during regular blood sampling intervals. 2015-09-15T13:08:37Z 2015-09-15T13:08:37Z 2015 Thesis http://hdl.handle.net/10539/18658 en application/pdf application/pdf
collection NDLTD
language en
format Others
sources NDLTD
topic Drug Delivery Systems
spellingShingle Drug Delivery Systems
Kondiah, Pierre Pavan Demarco
Development of versatile bio-stable oral polymeric delivery systems for proteins
description An oral proteomatrix drug delivery platform was formulated using pH responsive biostable polymers for slow release kinetics for the treatment of the neurodegenerative disease, multiple sclerosis (MS), which was the primary aim. After successful design and optimization for utilizing this system for MS, this system was further applied as a versatile platform for oral protein delivery. Interferon beta (INF- ) was selected as the oral treatment for MS. The fundamental effect of INF- in the treatment of MS is based on reducing the immune response that is directed against central nervous system myelin, i.e. the fatty sheath that surrounds and protects nerve fibers. Damage of nerve fibers, resulting in demyelination, consequently causes nerve impulses to be slowed or halted, thus producing symptoms of MS (Jongen et al., 2011). To date, INF- is effectively being used to treat MS subcutaneously or as intramuscular injections. These forms of administration have commonly been associated with multiple problems of pain, allergic reactions, poor patient compliance and chances of infection (Chiu et al., 2007). It was thus concluded to design an oral platform for the delivery of multiple protein therapeutic formulations. To prove the versatility of the proteomatrix system, two other demanding protein therapeutics for oral delivery, insulin and erythropoietin, were selected for further in vitro Box-Behnken series of formulations and in vivo analysis. By administration of these oral protein systems, a greater patient compliance can be achieved, thus enhancing the therapeutic profiles of patients with conditions of MS, diabetes and chronic renal failure resulting in chronic anemia. All studies consisted of in vitro drug release studies, characterization using specific analytical techniques for testing the mechanical properties, as well as the physicochemical characteristics of the copolymeric system. All proteins, INF- , insulin and erythropoietin, were analyzed in vivo using New Zealand White rabbits (NZW) with determination of the protein from serum obtained during regular blood sampling intervals.
author Kondiah, Pierre Pavan Demarco
author_facet Kondiah, Pierre Pavan Demarco
author_sort Kondiah, Pierre Pavan Demarco
title Development of versatile bio-stable oral polymeric delivery systems for proteins
title_short Development of versatile bio-stable oral polymeric delivery systems for proteins
title_full Development of versatile bio-stable oral polymeric delivery systems for proteins
title_fullStr Development of versatile bio-stable oral polymeric delivery systems for proteins
title_full_unstemmed Development of versatile bio-stable oral polymeric delivery systems for proteins
title_sort development of versatile bio-stable oral polymeric delivery systems for proteins
publishDate 2015
url http://hdl.handle.net/10539/18658
work_keys_str_mv AT kondiahpierrepavandemarco developmentofversatilebiostableoralpolymericdeliverysystemsforproteins
_version_ 1719083511761076224